ArriVent BioPharma, Inc.
ArriVent BioPharma, Inc. scores highest on Torque (65) and lowest on Earnings (20). Its PosiPenta is 39.97 out of 100, weaker than most similar companies.
On the Penta Grid this week, ArriVent BioPharma, Inc. is Grid #543 of 837 in the Healthcare sector in United States, and Grid #2,891 of 4,000 in United States.
Compared with similar companies in the Healthcare sector in United States.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| ArriVent BioPharma, Inc. | 39.97 | 26 | 20 | 46 | 65 | 43 |
| Monte Rosa Therapeutics, Inc. | 36.56 | 31 | 28 | 31 | 53 | 39 |
| Jade Biosciences, Inc. | 44.78 | 30 | 23 | 50 | 80 | 41 |
| SpyGlass Pharma, Inc. | 48.43 | 19 | 23 | 72 | 77 | 51 |
| MeiraGTx Holdings plc | 55.72 | 57 | 43 | 60 | 64 | 56 |
| Integra LifeSciences Holdings Corporation | 58.12 | 40 | 87 | 65 | 42 | 57 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | -4.60 |
| P/B ratio | 2.24 |
EEarnings
| Trailing EPS | ₹-342.87 |
| Forward EPS | ₹-365.63 |
NNitro
| Price | 1577.95 |
| 52-week high | 3393.64 |
| 52-week low | 1075.96 |
| Fall from 52-week high | 53.5% |
TTorque
| Return on equity (ROE) | -53.25% |
| Debt-to-equity | 0.00 |
AAnchor
| Beta (price swings) | 1.35 |
| Market cap | ₹7,780 Cr |
| Insider holding | 1.54% |
| Dividend yield | 0.00% |
Figures as used for the week of 17 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is ArriVent BioPharma, Inc.'s PosiPenta score?
ArriVent BioPharma, Inc.'s PosiPenta is 39.97 out of 100 for the week of 17 Oct 2026, based on 5 of 5 pillars.
Where does ArriVent BioPharma, Inc. stand on the Penta Grid?
On the Penta Grid this week, ArriVent BioPharma, Inc. is Grid #543 of 837 in the Healthcare sector in United States, and Grid #2,891 of 4,000 in United States.
Which PosiPenta pillar is strongest for ArriVent BioPharma, Inc.?
Torque (durability), with a score of 65 out of 100: better than most similar companies.
Which PosiPenta pillar is weakest for ArriVent BioPharma, Inc.?
Earnings (growth), with a score of 20 out of 100: much weaker than most similar companies.
Has ArriVent BioPharma, Inc.'s PosiPenta changed since last week?
Yes, it rose 3.77 points, from 36.20 to 39.97.
PositoAI is for research and education only and is not investment advice.